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Background: Cancer stem cells (CSCs) are able to self-renew and to form metastases. Using flow cytometry, CSCs
were detected in canine mammary tumors as cells CD44+ and CD24-. The aim of this study was to detect these
CSCs by immunohistochemistry and correlate their frequency with canine mammary neoplasm grade and
histopathological type.
130 mammary neoplasm samples were selected from tissue blocks at the Department of Pathology at UNESP and
classified according to (BJVP 4:153-180, 2011). These samples were composed by adenomas, lymph node
metastases, solid carcinomas grades II and III, tubular, papillary and carcinomas in mixed tumor grades I, II and III.
Immunohistochemistry was performed with antibodies against CD44 and CD24. Linear regression was performed
using Pearson’s correlation test.
Results: The value at CD44 was positive and CD24 becomes zero was 46.75%. Cells with a CD44+/CD24- phenotype
were detected in 40 out of 130 samples with an advantage of high grade tumors (II and III) and metastases among
tubular, papillary and carcinomas in mixed tumors. In these samples, percentages of cells stained by CD44 and
CD24 antibodies were 62.2% and 0%, respectively. Published reports usually correlate grade III tumors with the
expression of CD44 but not with CD24 expression. Studies using flow cytometry have found CSC frequencies similar
to those found in our study.
Conclusions: Immunohistochemistry was found to be a reliable technique for the detection of CSCs in canine
mammary neoplasms, and the frequency of these cells positively correlates with grades II and III tumors (poor prognosis).
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Stem cells have two major properties: the ability to
self-renew by being able to divide and form another
stem cell; and differentiation into new mature cells in
the organ were they reside [1].
Cancer Stem Cells (CSC) have properties which are
analogous to those of stem cells [2] and cannot be isolated
and characterized as a simple cell. Specific cell surface
markers for CSCs have been detected in human mammary
neoplasms which stain positive for CD44 and negative
or low for CD24. The discovery that these cell surface* Correspondence: erikaterra@ibest.com.br
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reproduction in any medium, provided the orreceptors can be used to define a CSC phenotype was
made after the implantation of human solid mammary
tumors in rats. The authors of that study demonstrated
that solid tumors contained a small distinct population of
cells with a unique ability to form tumors in non-obese,
diabetic, immunosuppressed rats and these cells were
named tumorigenic cells or cancer initiating cells [3].
For a better comprehension of these stem cells, the
authors of one study [4] created an in vitro model in which
CD44+/CD24- cells isolated by fluorescence-activated
cell sorting form mammospheres [3]. Mammospheres are
spherical colonies formed from one single non-adherent
cultured cell which is capable of inducing the formation of
tumors in rats.
CSCs have been observed in cultured cells derived from
canine mammary neoplasms [5], although cells bearing
self-renewal capacity were found to be rare. Cells fromtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Number of samples of canine mammary
neoplasms distributed by histological type and grade
Number of samples Histological type and grade
12 Grade I tubular carcinoma
12 Grade II tubular carcinoma
10 Grade III tubular carcinoma
10 Grade I papillary carcinoma
8 Grade II papillary carcinoma
8 Grade III papillary carcinoma
11 Grade II solid carcinoma
10 Grade III solid carcinoma
11 Grade I carcinoma in mixed tumor
11 Grade II carcinoma in mixed tumor
10 Grade III carcinoma in mixed tumor
8 Metastases
9 Adenomas
Table 2 Dilutions, clones and supplier of the antibodies
used in canine mammary neoplasm tissue sections
Antibodies Clones Dilutions Supplier
CD44, HCAM (M)* IM7 1:100 Santa Cruz, ref. 18849
CD24 (M) M1/69 1:75 Santa Cruz, ref. 19651
*M =Monoclonal antibody.
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were able to give rise to mammary ducts and alveoli
in vitro [6]. In another study using mammospheres, CSCs
in canine mammary neoplasms exhibited a CD44+/CD24-
phenotype in four different tumoral cell lines [7].
In another study with canine cancer cell lines (osteosar-
coma, melanoma, glioma and mammary tumor), CD44
expression was associated with proliferation, but the
authors concluded that the transient and fluctuating
expression may limit its utility as a CSC marker [8].
Abraham et al. [9] suggested that the CD44+/CD24-
phenotype is not associated with clinical prognosis or
survival time of human patients with mammary neoplasms,
but is associated with presence of distant metastases, such
as bone metastasis. Due to the high incidence of mammary
neoplasms in female dogs, which ranges from 50% [10]
to 68.4% [11] or 73.4% [12], immunodetection of CSCs
can prove valuable for therapeutic choice and prognosis
prediction in these patients. Thus, the aim of this study was
to identify the CD44 and CD24 expressions in different
canine mammary neoplasms, including benign, malignant
and lymph node metastatic sites, and correlate them with
histological grade of malignancy and histopatological type,
since no similar data has been found in the literature.
Methods
The present study was approved by the Ethics Committee
on Animal Use (protocol number: 025600–08). A total
of 130 mammary neoplasm samples (including benign,
malignant and lymph node metastases specimens) were
selected from the archives of the Veterinary Pathology
Department (FCAV/Unesp - Jaboticabal).
Malignant neoplasms were composed of grades I, II, and
III tubular, papillar, and carcinomas in mixed tumors and
grades II, and III solid carcinomas. Adenomas were also
selected. Lymph node metastases were randomly selected,
however their primary tumor was not included, they were
used as undifferentiated mammary neoplastic cells. All
neoplasms were reclassified and graded according to
the criteria proposed by [13], Table 1.
Immunohistochemical analysis
For immunohistochemical analysis, serial tissue sections
were made from paraffin-embedded mammary neoplasms
and stained using antibodies against CD44, and CD24, as
described in Table 2.
Immunohistochemistry was performed using a
polymer-based method
Formalin-fixed, paraffin-embedded tissue sections (4 μm
thickness) of neoplasms were deparaffinized in xylene and
rehydrated through graded concentrations of ethanol. After
inhibition of endogenous peroxidase activity with 10%
H2O2 (20 min), the antigen retrieval was achieved byheat treatment in a pressure cooker (Pascal, DAKO) in
Tris-EDTA buffer at pH 9.0 for the CD24 antibody. For
CD44 antibody, the antigen retrieval was carried out using
citrate buffer pH 6.0 also in a pressure cooker.
After three thorough washes with Tris–HCl solution
(pH 7.4) for 5 minutes, blocking for non-specific binding
was performed using a blocking solution (protein block
serum-free – DAKO ref. ×0909). Sections were incubated
with antibodies at optimal dilution (Table 2) for 18 hours
(overnight) at 4°C for CD24 and 1 hour at 28°C for CD44.
Then, the sections were incubated with a peroxidase-
conjugated polymer (kit ENVISION + Dual Link System
Peroxidase ref K4061 - DAKO) and diaminobenzidine
(DAB - DAKO, ref. K3466) was used as the chromogen.
Hematoxylin was used as the counterstain.
The primary antibody was replaced with antibody
diluent (Antibody Diluent with Background Reducing
Components, ref. S3022, DAKO) as a negative control.
Breast tumors tissue sections known to express these
markers were used as positive controls in each batch of
IHC analysis. The use of human material was approved by
the Research Ethics Committee of CHRP and FMRP/USP
(process 242/2011).
Quantification of stained cells
The type and distribution of stained cells were analyzed
before cell counts were performed. Four fields were
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cells. A total of 100 stained or non-stained cells were
counted using the 40× objective. Results were expressed in
percentage of stained cells. In the carcinomas in mixed
tumors group, only epithelial neoplastic cells were counted
because there was no labeling in mesenchymal and
myoepithelial cells. These epithelial cells correspond to
carcinomatous (malignant) areas of this tumor.
Statistical analysis
Data were analyzed using Pearson’s correlation test
followed by Simple Linear Regression using SAS software
(SAS 9.1, SAS Institute, Cary, NC, USA). The frequency
of histopathological types was analyzed using the 95%
confidence interval.
Results
Staining for CD44 was detected on the plasma membrane
(Figure 1A). In solid carcinomas, staining was seen on
myoepithelial cells and epithelial cells and was strongly
positive (Figure 1B). Conversely, in carcinomas in mixed
tumors, immunostaining for CD44 was seen on epithelial
cells but not in well-differentiated mesenchymal tissue or in
myoepithelial cells. Staining was strong on undifferentiated
metastatic cells in samples from lymph node metastastic
sites (Figure 1C). Staining for CD44 was more frequent inA
C
Figure 1 Immunostaining of CD44 and CD24 indifferent types of cani
carcinoma; note positive immunostaining for CD44 on the plasma membra
positive immunostaining for CD44 on the plasma membrane of neoplastic
membrane of undifferentiated epithelial cells. (D) Grade III solid carcinoma
cells subjected to immunohistochemistry for CD24. Sections stained with Dhigher-grade tumors. Staining for CD24 was detected
on the plasma membrane and in cytoplasm. In solid
carcinomas, samples which stained positive for CD44
were negative for CD24 (Figure 1D). Metastatic cells in
lymph nodes were likewise negative for CD24 (Figure 2A).
In general, there were more positive cells for CD24 in
grade I tumors (Figure 2B) compared to grade II and
III tumors.
Pearson’s correlation test performed on 130 samples
marked with anti-CD44 and anti-CD24 antibodies ex-
hibited a significant correlation with p = 0.0045. The
intercept value of 46.75% ± 2.34 indicates that increased fre-
quency of CD44+ cells correlates with decreased CD24+
cells. A regression line is shown in Figure 3.
Therefore, among the 130 samples analyzed, those that
were positive for this correlation are represented in
Table 3. From 130 samples, 40 (30%) expressed this
phenotype (CD44+/CD24-); of these, 37 were high-grade
tumors (II and III) and lymph node metastases and only
three samples were grade I neoplasms. The mean number
of cells which stained positive for CD44, and for CD24
in these samples was 62.2% and 0%, respectively. These
neoplasms exhibited a CD44+/CD24- phenotype.
Lymph nodes metastatic sites represented the major
frequency of positive cells for this phenotype (7/8; 87.5%;
CI 95% 51.75-97.19%).B
D
ne mammary neoplasms. Legend: (A) Grade II mixed tumor
nes of neoplastic epithelial cells. (B) Grade III solid carcinoma; note
epithelial cells. (C) Positive immunostaining for CD44 on the plasma
from a female dog; note absence of immunostaining on epithelial
AB and counterstained with Harris Hematoxylin. 40× obj.
Figure 3 Linear regression line between CD44 (y-axis) and CD24 (x-ax
positive and CD24 becomes zero is 46.75%.
A
B
Figure 2 CD24 Expressionin a canine malignant mammary
neoplasm and a lymph node metastasis. Legend: (A) Note
absence of immunostaining for CD24 on metastatic cells (arrow) in
a lymph node. 40× obj. (B) Grade I mixed tumor carcinoma from
a female dog; note positive immunostaining for CD24 on the
plasma membrane and in the cytoplasm of neoplastic epithelial
cells. 40× obj.
Table 3 Identification of canine mammary neoplasms
expressing a CD44+/CD24- phenotype
Neoplasm Number of samples with a
CD44+/CD24cp phenotype
Grade I Tubular carcinoma 1 (2,5%)
Grade II Tubular carcinoma 5 (12,5%)
Grade III Tubular carcinoma 5 (12,5%)
Grade I Papillary carcinoma 1 (2,5%)
Grade II Papillary carcinoma 3 (7,5%)
Grade III Papillary carcinoma 4 (10%)
Grade II Solid carcinoma 1 (2,5%)
Grade III Solid carcinoma 2 (5%)
Grade I carcinoma in mixed tumor 1 (2,5%)
Grade II carcinoma in mixed tumor 4 (10%)
Grade III carcinoma in mixed tumor 6 (15%)
Metastases 7 (17,5%)
Total 40 (100%)
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phenotype was carcinoma in mixed tumors (11/32, 34.37%;
CI 95% 36.21-57.76%), followed by tubular carcinomas
(11/34; 32.35%; CI 95% 19.13-49.29%), papillary carcinomas
(8/26; 30.77%; CI 95% 16.52-50.18%) and solid carcin-
omas (3/21, 14.29%; CI 95% 5.19-34.91%).
Discussion
Other authors have detected a CD44+/CD24- phenotype
in 91.9, 93.0, 76.2, and 44.3% of four different cell lines
from canine mammary neoplasms using flow cytome-
try [7], however the immunohistochemical expression
of these proteins was not demonstrated in canine
mammary neoplasms. The percentages of cells bearing the
CD44+/CD24- phenotype as assessed by immunohisto-
chemistry in this study are very similar to those values foris) using Pearson’s correlation test. The value at which CD44 is
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viewed as a good technique for the detection of CSCs in
canine mammary neoplasms.
The percentage of cells which express this phenotype
in human mammary neoplasms varies significantly.
One study found a variation of 2% to 40% in the num-
ber CSCs detected by immunohistochemistry and, also,
a high association of these cells with tumor grade and
aggressiveness [14].
Of the 40 neoplasms with the CD44+/CD24- phenotype
described in our study, 37 exhibited histological grades
II or III, or were of lymph node metastases. Only three
samples corresponded to grade I neoplasms. Other authors
have found more CSCs in grade III (undifferentiated) than
in grade I (well differentiated) human mammary neoplasms
[15]. When these results were applied to the meta-analysis
of breast cancer expression data sets, they found that it
was predictive of biological and molecular features of
human breast cancers and concluded that breast cancers
can be distinguished based on their degree of resemblance
to the CSCs molecular phenotype.
The most frequent histopathological type showing this
CD44+/CD24- was carcinoma in mixed tumors, followed
by tubular, pappilary and solid carcinomas. In solid carcin-
omas, only three of 21 grade II or III mammary carcinomas
evaluated in this study exhibited this phenotype.
Studies involving CSCs markers started with solid mam-
mary tumors. Al-Hajj et al. [3] stated that solid tumors
exhibited a distinct population of cells with a select ability
to form tumors in rats and named them tumorigenic cells
or cancer initiating cells because they were really able
to give rise to new neoplasms. However, the isolation
of CSCs in solid tumors has been difficult for several
reasons. Cells from solid tumors are generally less access-
ible than normal stem cells in developing organs, and their
detection and quantification require different functional
assays as well [16]. In our study, the number of cells
with a CD44+/CD24- phenotype was higher in the other
histological types than in solid carcinomas, indicating
that although this phenotype correlates with the worst
histopathological grades, the prognostic association with
histological type should be investigated.
Seven of 8 samples from lymph node metastases analyzed
had the CD44+/CD24- phenotype. Other study has found
similar, but not identical, results since the authors com-
pared neoplastic cells in lymph nodes metastases with their
corresponding primary tumor and found that metastatic
cells contained a higher frequency of CD44+/CD24- cells
[17]. In our study, the metastatic lymph nodes were not
evaluated with their primary tumors, but this fact is
nonetheless likely to demonstrate that metastatic sites
cells can have a higher population of cancer stem cells.
This CSC phenotype has also been detected in lympho-
vascular emboli of inflammatory breast carcinoma inwomen [18]. Another study using flow cytometry
showed that 6.1% of the lymph node metastases contained
CD44+/CD24- cells and found an association between
metastatic dissemination and increased numbers of cells
with this phenotype in human mammary neoplasms [19].
Some researchers believe that the cells that are able to mi-
grate to metastatic sites are the CSCs [20]. There are so
many pathways involved in metastatic process and one of
the most important is the EMT (epithelial-mesenchymal
transition) which is associated with a gain of stem cell-like
behaviour. The most important steps for distant metasta-
sis are dissemination through a fine net of blood vessels
and colonization at the metastatic site. In contrast to
undifferentiated, anaplastic primary tumours, cells from
differentiated tumours are not expected to possess the
necessary traits with which to disseminate, nevertheless
they also metastasize [21], this way a correlation between
cells in primary tumors and in their metastatic site is not
always logic.
Conclusion
The CD44+/CD24- phenotype can be detected by immu-
nohistochemistry and is related to the most aggressive
tumor grades in canine mammary neoplasms.
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